Takeda Pharmaceutical, Eisai, and Nippon Chemiphar offeredearly retirement programs over the past year, a Jiho survey revealed. It appears that not all of them are looking at downsizing, however, with some aggressively seeking to “rejuvenate” their employees by replacing ones…
HOME > BUSINESS
BUSINESS
- Drug Makers’ Female Manager Ratio at 12.5%; Major Gap between Japan, Foreign Players
April 30, 2021
- Shionogi, InveniAI Ink Drug Discovery Collaboration
April 30, 2021
- 300 Million Yen Fine Sought for Toho Too, Court Decision Due June 2: Bid-Rigging Trial
April 30, 2021
- Takeda’s Mobocertinib Gets FDA’s Priority Review for EGFR Exon 20-Mutant NSCLC
April 30, 2021
- Pfizer Japan Posts 251 Billion Yen Sales in FY2020 after Upjohn Spinoff
April 30, 2021
- Amgen Files KRAS Inhibitor Sotorasib in Japan for NSCLC
April 30, 2021
- Court’s Settlement Offer on Opdivo Royalty Dispute Fails
April 28, 2021
- Prosecutors Seek 300 Million Yen Fine for Suzuken, Jail Terms for Employees: Bid-Rigging Trial
April 28, 2021
- Takeda, Eisai, Chemiphar Ran Early Retirement Programs over Past Year: Survey
April 28, 2021
- Boehringer’s Japan Pharma Sales Rise 3.1% in 2020 on Ofev, Jardiance
April 28, 2021
- Daiichi Sankyo Sales Slip in FY2020 as Price Cuts, Deal Termination Weigh
April 28, 2021
- Xtandi Bullish, but Astellas Sales Wane 3.9% on Deal Wind-Ups; Profits Dip after Gene Therapy Trial Hold
April 28, 2021
- Daiichi Sankyo Gets Brazil, South Korea Rights to Esperion’s Hypercholesterolemia Drug
April 28, 2021
- AbbVie Files Maviret for Use in Children Age 3 Plus
April 28, 2021
- Nihon Generic Recalling Metformin Products over Carcinogen Risks
April 27, 2021
- SymBio’s Brincidofovir Gets FDA’s Fast-Track Status
April 27, 2021
- Kyorin Grabs Distribution Rights to MSD’s Cough Medicine in Japan
April 27, 2021
- Lilly, Daiichi Sankyo Roll Out Migraine Drug Emgality in Japan
April 27, 2021
- Novartis Offering Voluntary Redundancy for 3rd Consecutive Year, Targets Sales & Medical across Therapeutic Areas
April 27, 2021
- NanoCarrier, Axcelead Forge JV to Develop mRNA-Driven Articular Cartilage Drug
April 27, 2021
ページ
The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
The past month has seen two significant milestones in healthcare price control measures in Japan: The first “off-year” NHI reimbursement price cuts, and release of the first results under Japan’s “cost-effectiveness assessment” system. Both milestones have been anticipated for quite…